요로상피암 진단 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Urothelial Carcinoma Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,942,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,138,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,806,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

전 세계 요로상피암 진단 시장 규모는 2025년에 18억 4,480만 달러로 2025-2032년 예측 기간 동안 10.9%의 CAGR로 확대되어 2032년에는 38억 3,130만 달러에 달할 것으로 예상됩니다.

일반적으로 방광암으로 불리는 요로상피암은 효과적인 치료와 환자 예후를 위해 조기에 정확한 진단이 필요한 악성 종양입니다. 요로상피암 진단 시장에는 요세포검사, 바이오마커 검사, 형광 in situ hybridization(FISH), 방광경 검사, 영상 기술 등 다양한 진단법이 포함됩니다. 이러한 진단법은 질병의 발견, 병기 결정 및 재발 모니터링에 중요한 역할을 하고 있습니다. 시장 성장의 원동력은 진단 기술의 발전, 방광암 발병률 증가, 비침습적 진단 접근법 채택 확대, 환자 편의성 및 조기 발견율 향상입니다.

세계 요로상피암 진단 시장은 고령화 사회와 흡연 및 산업 화학제품 노출과 같은 고위험 요인을 가진 사람들 사이에서 방광암 유병률이 증가하는 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 또한, 소변 기반 바이오마커 검사와 같은 비침습적, 최소침습적 진단 방법에 대한 선호도가 높아지는 것도 시장 확대에 기여하고 있습니다. 또한, 분자진단 및 인공지능을 활용한 영상 진단 솔루션의 기술 발전으로 진단의 정확성과 효율성이 향상되고 있습니다. 액체 생검과 차세대 염기서열분석(NGS)의 통합이 진행되면서 요로상피암 환자들에게 정확하고 개인화된 진단 인사이트를 제공함으로써 시장 성장을 더욱 촉진하고 있습니다.

요로상피암 진단 시장은 영상 진단에서 인공지능과 머신러닝의 채택 증가, 정밀의료 접근법의 확대, 조기 암 발견 프로그램에 대한 관심 증가로 인해 큰 성장 기회를 맞이할 것으로 보입니다. 디지털 병리학 및 AI 지원 진단 플랫폼의 발전은 진단 효율성을 높이고, 위양성 또는 위음성의 가능성을 줄이며, 환자 결과를 개선할 수 있습니다. 또한, 요로상피암에 대한 비용 효율적이고 신속한 현장 진단 솔루션의 개발은 의료 서비스가 부족한 지역에서의 시장 개척을 촉진할 수 있습니다. 바이오마커의 발견과 검증을 위한 진단 기업과 연구기관의 제휴도 이 성장 중인 시장에서 유리한 성장 전망을 가져다 줄 수 있습니다.

세계의 요로상피암 진단 시장에 대해 조사했으며, 제품별, 검사별, 최종사용자별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
• 거시경제 요인
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 요로상피암 진단 시장 전망

• 주요 하이라이트
• 시장 규모 분석과 예측
• 세계의 요로상피암 진단 시장 전망 : 제품별
• 세계의 요로상피암 진단 시장 전망 : 검사별
• 세계의 요로상피암 진단 시장 전망 : 최종사용자별

제5장 세계의 요로상피암 진단 시장 전망 : 지역별

• 주요 하이라이트
• 시장 규모의 역사적 분석, 지역별, 2019-2024년
• 현재 시장 규모 분석과 예측, 지역별, 2025-2032년
• 시장 매력 분석 : 지역별

제6장 북미의 요로상피암 진단 시장 전망

제7장 유럽의 요로상피암 진단 시장 전망

제8장 동아시아의 요로상피암 진단 시장 전망

제9장 남아시아 및 오세아니아의 요로상피암 진단 시장 전망

제10장 라틴아메리카의 요로상피암 진단 시장 전망

제11장 중동 및 아프리카의 요로상피암 진단 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석, 2025년
• 시장 구조
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • Roche Holding
  • Illumina
  • IDL Biotech
  • Agilent Technologies
  • Olympus Corporation
  • Philips Healthcare
  • Abbott Molecular
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.(Qiagen NV)
  • Danaher Corporation(Cepheid)
  • GE Healthcare
  • Pacific Edge
  • Nonacus Limited
  • KDx Diagnostics Inc.
  • Sysmex Europe SE

제13장 부록

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for urothelial carcinoma diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global urothelial carcinoma diagnostics market from 2025 to 2032.

Key Insights:

• Urothelial Carcinoma Diagnostics Market Size (2025E): US$ 1,844.8 Mn
• Projected Market Value (2032F): US$ 3,831.3 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 10.9%

Urothelial Carcinoma Diagnostics Market - Report Scope:

Urothelial carcinoma, commonly referred to as bladder cancer, is a prevalent malignancy requiring early and accurate diagnostics for effective treatment and patient outcomes. The market for urothelial carcinoma diagnostics includes a range of diagnostic modalities such as urine cytology, biomarker testing, fluorescence in situ hybridization (FISH), cystoscopy, and imaging techniques. These diagnostics play a crucial role in disease detection, staging, and monitoring recurrence. Market growth is driven by advancements in diagnostic technologies, increasing bladder cancer incidence, and the growing adoption of non-invasive diagnostic approaches, improving patient convenience and early detection rates.

Market Growth Drivers:

The global urothelial carcinoma diagnostics market is propelled by several key factors, including the rising prevalence of bladder cancer, particularly among aging populations and individuals with high-risk factors such as smoking and exposure to industrial chemicals. The growing preference for non-invasive and minimally invasive diagnostic methods, such as urine-based biomarker tests, is also contributing to market expansion. Additionally, technological advancements in molecular diagnostics and artificial intelligence-driven imaging solutions are enhancing diagnostic accuracy and efficiency. The increasing integration of liquid biopsy and next-generation sequencing (NGS) further supports market growth by offering precise, personalized diagnostic insights for urothelial carcinoma patients.

Market Restraints:

Despite promising growth prospects, the urothelial carcinoma diagnostics market faces challenges related to high diagnostic costs, limited accessibility in low-income regions, and reimbursement constraints. Many advanced diagnostic tests, including biomarker-based assays and genetic testing, remain expensive, limiting their widespread adoption in cost-sensitive markets. Furthermore, the complexity of regulatory approvals for novel diagnostic techniques poses barriers to market entry and innovation. Addressing these challenges requires collaboration among diagnostic manufacturers, healthcare providers, and policymakers to enhance affordability, accessibility, and regulatory harmonization.

Market Opportunities:

The urothelial carcinoma diagnostics market presents significant growth opportunities driven by the increasing adoption of artificial intelligence and machine learning in diagnostic imaging, the expansion of precision medicine approaches, and the rising focus on early cancer detection programs. Advancements in digital pathology and AI-assisted diagnostic platforms enhance diagnostic efficiency and reduce the likelihood of false positives or negatives, improving patient outcomes. Additionally, the development of cost-effective, rapid point-of-care diagnostic solutions for urothelial carcinoma could drive market penetration in underserved regions. Partnerships between diagnostic companies and research institutions to advance biomarker discovery and validation also offer lucrative growth prospects in this evolving market.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the urothelial carcinoma diagnostics market globally?
• Which diagnostic modalities are witnessing the highest adoption in urothelial carcinoma detection and management?
• How are technological advancements influencing the competitive landscape of the urothelial carcinoma diagnostics market?
• Who are the key players contributing to the urothelial carcinoma diagnostics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global urothelial carcinoma diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urothelial carcinoma diagnostics market, including Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, and Bio-Rad Laboratories, focus on technological innovation, strategic collaborations, and product development to gain a competitive edge. These companies invest heavily in R&D to develop novel biomarker assays, liquid biopsy solutions, and AI-driven imaging tools for early and accurate detection of urothelial carcinoma. Partnerships with academic institutions and clinical research organizations facilitate the advancement of precision oncology diagnostics. Additionally, efforts to improve accessibility and affordability through pricing strategies, reimbursement advocacy, and expansion into emerging markets further support market growth.

Key Companies Profiled:

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Qiagen N.V.
• Agilent Technologies
• Illumina, Inc.
• Siemens Healthineers
• BD (Becton, Dickinson and Company)
• Hologic, Inc.

Urothelial Carcinoma Diagnostics Market Segmentation

By Product

• Reagent and Kits
• Instruments

By Test

• Urinalysis Test
• Molecular Diagnostic Test
• Biomarker Test

Cell-Based Test

• Imaging Test
• Cystoscopy
• Ureteroscopy

By End User

• Hospitals
• Diagnostic Laboratories
• Research and Academic Institutes
• Clinical Research Organizations

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Urothelial Carcinoma Diagnostics Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Urothelial Carcinoma Diagnostics Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Urothelial Carcinoma Diagnostics Market Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 4.3.3.1. Reagent and Kits
    • 4.3.3.2. Instruments
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Urothelial Carcinoma Diagnostics Market Outlook: Test
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Test, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 4.4.3.1. Urinalysis Test
    • 4.4.3.2. Molecular Diagnostic Test
    • 4.4.3.3. Biomarker Test
      • 4.4.3.3.1. Immuno-Histochemical Assay Test
      • 4.4.3.3.2. In Situ Hybridization Test
      • 4.4.3.3.3. Biopsy
      • 4.4.3.3.4. Cell-Based Test
    • 4.4.3.4. Imaging Test
    • 4.4.3.5. Cystoscopy
    • 4.4.3.6. Ureteroscopy
  • 4.4.4. Market Attractiveness Analysis: Test
• 4.5. Global Urothelial Carcinoma Diagnostics Market Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.5.3.1. Hospitals
    • 4.5.3.2. Diagnostic Laboratories
    • 4.5.3.3. Research and Academic Institutes
    • 4.5.3.4. Clinical Research Organizations
  • 4.5.4. Market Attractiveness Analysis: End User

5. Global Urothelial Carcinoma Diagnostics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Urothelial Carcinoma Diagnostics Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Test
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 6.4.1. Reagent and Kits
  • 6.4.2. Instruments
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
  • 6.5.1. Urinalysis Test
  • 6.5.2. Molecular Diagnostic Test
  • 6.5.3. Biomarker Test
    • 6.5.3.1. Immuno-Histochemical Assay Test
    • 6.5.3.2. In Situ Hybridization Test
    • 6.5.3.3. Biopsy
    • 6.5.3.4. Cell-Based Test
  • 6.5.4. Imaging Test
  • 6.5.5. Cystoscopy
  • 6.5.6. Ureteroscopy
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.6.1. Hospitals
  • 6.6.2. Diagnostic Laboratories
  • 6.6.3. Research and Academic Institutes
  • 6.6.4. Clinical Research Organizations
• 6.7. Market Attractiveness Analysis

7. Europe Urothelial Carcinoma Diagnostics Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Test
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 7.4.1. Reagent and Kits
  • 7.4.2. Instruments
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
  • 7.5.1. Urinalysis Test
  • 7.5.2. Molecular Diagnostic Test
  • 7.5.3. Biomarker Test
    • 7.5.3.1. Immuno-Histochemical Assay Test
    • 7.5.3.2. In Situ Hybridization Test
    • 7.5.3.3. Biopsy
    • 7.5.3.4. Cell-Based Test
  • 7.5.4. Imaging Test
  • 7.5.5. Cystoscopy
  • 7.5.6. Ureteroscopy
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.6.1. Hospitals
  • 7.6.2. Diagnostic Laboratories
  • 7.6.3. Research and Academic Institutes
  • 7.6.4. Clinical Research Organizations
• 7.7. Market Attractiveness Analysis

8. East Asia Urothelial Carcinoma Diagnostics Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Test
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 8.4.1. Reagent and Kits
  • 8.4.2. Instruments
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
  • 8.5.1. Urinalysis Test
  • 8.5.2. Molecular Diagnostic Test
  • 8.5.3. Biomarker Test
    • 8.5.3.1. Immuno-Histochemical Assay Test
    • 8.5.3.2. In Situ Hybridization Test
    • 8.5.3.3. Biopsy
    • 8.5.3.4. Cell-Based Test
  • 8.5.4. Imaging Test
  • 8.5.5. Cystoscopy
  • 8.5.6. Ureteroscopy
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.6.1. Hospitals
  • 8.6.2. Diagnostic Laboratories
  • 8.6.3. Research and Academic Institutes
  • 8.6.4. Clinical Research Organizations
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Urothelial Carcinoma Diagnostics Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Test
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 9.4.1. Reagent and Kits
  • 9.4.2. Instruments
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
  • 9.5.1. Urinalysis Test
  • 9.5.2. Molecular Diagnostic Test
  • 9.5.3. Biomarker Test
    • 9.5.3.1. Immuno-Histochemical Assay Test
    • 9.5.3.2. In Situ Hybridization Test
    • 9.5.3.3. Biopsy
    • 9.5.3.4. Cell-Based Test
  • 9.5.4. Imaging Test
  • 9.5.5. Cystoscopy
  • 9.5.6. Ureteroscopy
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.6.1. Hospitals
  • 9.6.2. Diagnostic Laboratories
  • 9.6.3. Research and Academic Institutes
  • 9.6.4. Clinical Research Organizations
• 9.7. Market Attractiveness Analysis

10. Latin America Urothelial Carcinoma Diagnostics Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Test
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 10.4.1. Reagent and Kits
  • 10.4.2. Instruments
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
  • 10.5.1. Urinalysis Test
  • 10.5.2. Molecular Diagnostic Test
  • 10.5.3. Biomarker Test
    • 10.5.3.1. Immuno-Histochemical Assay Test
    • 10.5.3.2. In Situ Hybridization Test
    • 10.5.3.3. Biopsy
    • 10.5.3.4. Cell-Based Test
  • 10.5.4. Imaging Test
  • 10.5.5. Cystoscopy
  • 10.5.6. Ureteroscopy
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.6.1. Hospitals
  • 10.6.2. Diagnostic Laboratories
  • 10.6.3. Research and Academic Institutes
  • 10.6.4. Clinical Research Organizations
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Urothelial Carcinoma Diagnostics Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Test
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 11.4.1. Reagent and Kits
  • 11.4.2. Instruments
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
  • 11.5.1. Urinalysis Test
  • 11.5.2. Molecular Diagnostic Test
  • 11.5.3. Biomarker Test
    • 11.5.3.1. Immuno-Histochemical Assay Test
    • 11.5.3.2. In Situ Hybridization Test
    • 11.5.3.3. Biopsy
    • 11.5.3.4. Cell-Based Test
  • 11.5.4. Imaging Test
  • 11.5.5. Cystoscopy
  • 11.5.6. Ureteroscopy
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.6.1. Hospitals
  • 11.6.2. Diagnostic Laboratories
  • 11.6.3. Research and Academic Institutes
  • 11.6.4. Clinical Research Organizations
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Roche Holding
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Illumina
  • 12.3.3. IDL Biotech
  • 12.3.4. Agilent Technologies
  • 12.3.5. Olympus Corporation
  • 12.3.6. Philips Healthcare
  • 12.3.7. Abbott Molecular
  • 12.3.8. Bio-Rad Laboratories, Inc.
  • 12.3.9. Thermo Fisher Scientific, Inc. (Qiagen N.V.)
  • 12.3.10. Danaher Corporation (Cepheid)
  • 12.3.11. GE Healthcare
  • 12.3.12. Pacific Edge
  • 12.3.13. Nonacus Limited
  • 12.3.14. KDx Diagnostics Inc.
  • 12.3.15. Sysmex Europe SE

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료